Alkoholavhengighet
Sist oppdatert: Sist revidert:
Sist revidert av:Ingard LøgeDefinisjon:
Er en alvorlig og ofte langvarig tilstand assosiert med en sterk og vanskelig kontrollerbar trang til å innta alkohol
Forekomst:
Prevalens av alkoholavhengighet regnes å være ca. 4-5% av befolkningen i vestlige land
Symptomer:
Sykehistorien er karakterisert ved overforbruk av alkohol både over lengre tid og som hyppige kortvarige episoder
Funn:
I tidlig fase er det ingen kliniske funn. På lengre sikt inntrer utfall fra en rekke organsystemer
Diagnostikk:
Skadelig forbruk kan utredes med GT, ALAT, PEth, ev. CDT
Behandling:
Fundamentet i behandlingen er erkjennelse av problemet, og motivasjon for å slutte med misbruket
- Nasjonal kompetansetjeneste for tverrfaglig spesialisert rusbehandling - TSB
- Nasjonal kompetansetjeneste for samtidig rusmisbruk og psykisk lidelse - ROP
- Folkehelserapporten. Rusbrukslidelser i Norge. Folkehelseinstituttet, oppdatert 06.12.2019. fhi.no
- Skjøtskift S. Alkohol som medvirkende faktor i noen vanlige kliniske situasjoner. Tidsskr Nor Lægeforen 2003; 123: 185-7. PubMed
- O`Dowd. Alcohol accounts for 6% of all admissions til English hospitals. BMJ 2008; 337: a963. PubMed
- Tolstrup JS, Nordestgaard BG, Rasmussen S, Tybjærg-Hansen A, Grønbæk M. Genetisk variation i alkoholdehydrogenase, alkoholdrikkevaner og alkoholisme - sekundærpublikation. Ugeskr Læger 2008; 170: 2672. PubMed
- Schumann G, Liu C, O'Reilly P, et al. KLB is associated with alcohol drinking, and its gene product β-Klotho is necessary for FGF21 regulation of alcohol preference. Proc Natl Acad Sci USA 2016; 113:14372. doi: 10.1073/pnas.1611243113 DOI
- Crawford MJ, Patton R, Touquet T, et al. Screening and referral for brief intervention of alcohol-misusing patients in an emergency department: a pragmatic randomised controlled trial. Lancet 2004; 364: 1334-9. PubMed
- Brown RL, Saunders LA, Bobula JA, Lauster MH. Remission of alcohol disorders in primary care patients. J Fam Pract 2000; 49: 522-8. PubMed
- Braut GS. Krav til rusmiddelarbeid i helsetenesta. Tidsskr Nor Lægeforen 2003; 123: 49-51. PubMed
- Nordlie E. Alkoholmisbruk - hvilke konsekvenser har det for familiemedlemmene?. Tidsskr Nor Lægeforen 2003; 123: 52-4. PubMed
- Winslow BT, Onysko M. Medications for alcohol use disorder. Am Fam Physician. 2016 Mar 15;93(6):457-465.
- Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings. A systematic review and meta-analysis. JAMA 2014; 311: 1889-900. doi:10.1001/jama.2014.3628. DOI
- Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occuring depression and alcohol dependence. Am J Psychiatry 2010; 167: 668-75. American Journal of Psychiatry
- Pani PP, Trogu E, Pacini M, et al. Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev. 2014 Feb 13;2:CD008544. The Cochrane Library
- Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 2002; 17: 349-55. PubMed
- Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial . Lancet 2003; 361: 1677-85. PubMed
- Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med 2008; 359: 715-21. PubMed
- Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD001867. DOI: 10.1002/14651858.CD001867.pub3. DOI
- Carmen B, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99: 811-28. PubMed
- Berglund M, Thelander S, Salaspuro M et al. Treatment of alcohol abuse: An evidence-based review. Alcohol Clin Exp Res 2003; 27: 1645-56. PubMed
- Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE Study: a randomized controlled trial. JAMA 2006; 295: 2003-17. Journal of the American Medical Association
- Bouza C, Magro A, Munoz A, Amate J. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99: 811-8. PubMed
- Palpacuer C, Laviolle B, Boussageon R, et al. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: A systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 2015. doi: 10.1371/journal.pmed.1001924 DOI
- Mørland J. Legemidler mot alkoholmisbruk. Tidsskr Nor Lægeforen 2006; 126: 3268-9. PubMed
- Heilig M, Egli M. Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms. Pharmacol Ther 2006; 111: 855-76. PubMed
- Rosner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews 2010; 9: CD004332. Cochrane (DOI)
- Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings. A Systematic Review and Meta-analysis. JAMA. 2014 14;311(18):1889-900. doi: 10.1001/jama.2014.3628. DOI
- Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol dependent individuals: Results of a metaanalysis. Alcohol Clin Exp Res 2004; 28: 51-63. PubMed
- Namkoong K, Lee BQ, Lee PG et al. Acamprosate in Korean alcohol-dependent patients: A multi-centre, randomized, double-blind, placebo controlled study. Alcohol Alcohol 2003; 28: 135 - 41. PubMed
- Johnson BA, Rosenthal N, Capece JA, et al, for the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298: 1641-51. Journal of the American Medical Association
- Mason BJ, Quello S, Goodell V, et al. Gabapentin treatment for alcohol dependence: A randomized clinical trial. JAMA Intern Med 2013. doi:10.1001/jamainternmed.2013.11950 DOI
- Foster T. Editorial. Dying for a drink. BMJ 2001; 323: 817-8. PubMed
- Ingard Løge, spesialist i allmennmedisin, Trondheim
Tidligere fagmedarbeidere
- Svein Skjøtskift, spesialist i psykiatri, overlege, Bjørgvin Familierådgivningskontor, Bergen